In Vitro and In Vivo Activity of a Synthetic Halogenated Quinoline Against Cryptococcus neoformans

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Cryptococcus neoformans is an opportunistic fungal pathogen causing severe infections, particularly in immunocompromised individuals.
• There is a need for novel antifungal agents to combat emerging drug resistance and improve treatment outcomes.

Purpose of the Study:

• To evaluate the in vitro antifungal activity of 3-amino-7-chloro-3,4-dihydro-1-hydroxycarbostyril (CBS) against clinical strains of Cryptococcus neoformans.
• To assess the in vivo efficacy and toxicity of CBS in a murine model of cryptococcosis.

Main Methods:

• Minimum inhibitory concentrations (MICs) of CBS were determined against nine clinical isolates of C. neoformans using standard in vitro susceptibility testing.
• In vivo studies involved infecting mice with C. neoformans and administering varying doses of CBS to assess survival and toxicity.

Main Results:

• CBS exhibited fungistatic activity against several C. neoformans strains at a minimum concentration of 0.2 µg/ml after 48 hours.
• Treatment with CBS in infected mice significantly increased mean life expectancy compared to untreated controls.
• No significant toxicity was observed in the treated animal groups during the in vivo studies.

Conclusions:

• 3-amino-7-chloro-3,4-dihydro-1-hydroxycarbostyril (CBS) shows promising in vitro and in vivo antifungal activity against Cryptococcus neoformans.
• CBS represents a potential candidate for further development as a therapeutic agent for cryptococcosis.
• Further research is warranted to elucidate the mechanism of action and optimize the therapeutic potential of CBS.